A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

Next Previous
Trial Profile

A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs PLX R18 (Primary)
  • Indications Haematological disorders
  • Focus Adverse reactions
  • Sponsors Pluristem Therapeutics

    • Most Recent Events

    • 26 Oct 2017 According to a Pluristem media release, the company has received approval from Israels Ministry of Health to initiate this trial in Israel. Trial centres in Israel are Hadassah Medical Center and Rambam Hospital . Ethics committees at both centres have cleared the trial and recruitment can begin in both hospitals.
    • 23 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 15 Nov 2016 According to a Pluristem media release, Dr. Hillard Lazarus of Case Western Reserve University has been appointed as the Principal Investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top